Matching articles for "Ryaltris"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • January 23, 2023; (Issue 1668)
The FDA has approved Ryaltris (Hikma), a fixed-dose
combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase,
and generics) and the corticosteroid mometasone
furoate...
The FDA has approved Ryaltris (Hikma), a fixed-dose
combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase,
and generics) and the corticosteroid mometasone
furoate (Nasonex 24 HR Allergy, and generics), for
treatment of seasonal allergic rhinitis symptoms
in persons ≥12 years old. Ryaltris is the second
intranasal antihistamine/corticosteroid combination
to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which
is approved for use in persons ≥6 years old, was the
first. Both products are available only by prescription.